

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1.-24. (Canceled).

25. (Currently amended) An enriched or purified preparation of human mitotic oligodendrocyte-specified progenitor cells, the majority of which mature into oligodendrocytes, wherein the mitotic oligodendrocyte-specified progenitor cells are from a post-natal human and a human cyclic nucleotide phosphodiesterase gene P2 2 promoter is transcriptionally active in the oligodendrocyte progenitor cells ~~all cells of the enriched or purified preparation~~.

26. (Currently amended) An enriched or purified preparation of human mitotic oligodendrocyte progenitor cells, the majority of which mature into oligodendrocytes, wherein the mitotic oligodendrocyte progenitor cells are from an adult human and a human cyclic nucleotide phosphodiesterase gene P2 2 promoter is transcriptionally active in the oligodendrocyte progenitor cells ~~all cells of the enriched or purified preparation~~.

27.-28. (Canceled)

29. (Currently Amended) An enriched or purified preparation of human mitotic oligodendrocyte-specified progenitor cells, the majority of which mature into oligodendrocytes, wherein the oligodendrocyte progenitor cells express A2B5 antigen and do not express O4 antigen ~~a human cyclic nucleotide phosphodiesterase 2 promoter is transcriptionally active in all cells of the enriched or purified preparation~~.

30. (New) An enriched or purified preparation of human mitotic oligodendrocyte progenitor cells, the majority of which mature into oligodendrocytes, wherein the mitotic oligodendrocyte progenitor cells are from a fetal human and a human cyclic nucleotide phosphodiesterase gene P2 promoter is transcriptionally active in the oligodendrocyte progenitor cells.

31. (New) The enriched or purified preparation of claim 25, wherein the oligodendrocyte progenitor cells do not express GFAP antigen.

32. (New) The enriched or purified preparation of claim 26, wherein the oligodendrocyte progenitor cells do not express GFAP antigen.

33. (New) The enriched or purified preparation of claim 29, wherein the oligodendrocyte progenitor cells do not express GFAP antigen.

34. (New) The enriched or purified preparation of claim 30, wherein the oligodendrocyte progenitor cells do not express GFAP antigen.

35. (New) The enriched or purified preparation of claim 25, wherein the oligodendrocyte progenitor cells do not express β III tubulin antigen.

36. (New) The enriched or purified preparation of claim 26, wherein the oligodendrocyte progenitor cells do not express β III tubulin antigen.

37. (New) The enriched or purified preparation of claim 29, wherein the oligodendrocyte progenitor cells do not express β III tubulin antigen.

38. (New) The enriched or purified preparation of claim 30, wherein the oligodendrocyte progenitor cells do not express β III tubulin antigen.

39. (New) The enriched or purified preparation of claim 29, wherein the oligodendrocyte progenitor cells are from an adult human.

40. (New) The enriched or purified preparation of claim 29, wherein the oligodendrocyte progenitor cells are from a fetal human.

41. (New) The enriched or purified preparation of claim 29, wherein a human cyclic nucleotide phosphodiesterase gene P2 promoter is transcriptionally active in the oligodendrocyte progenitor cells.